Injectafer (Iron)

Ferric carboxymaltose is a stable iron‑carbohydrate complex. After intravenous infusion, the complex is taken up by macrophages of the reticuloendothelial system, where iron is released in a controlled fashion. The released iron binds to transferrin, is delivered to the bone marrow for hemoglobin synthesis, and replenishes peripheral iron stores.

The dose of Injectafer is individualized by the prescribing clinician based on the patient’s iron deficit, body weight, and clinical condition. The healthcare professional determines the total elemental iron required and the infusion rate, following approved prescribing information and local guidelines.

The safety of Injectafer in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a careful risk‑benefit assessment.

To order Injectafer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Injectafer (ferric carboxymaltose) delivers a larger single‑dose of elemental iron compared with iron sucrose or iron gluconate, allowing fewer infusion sessions. Its stable complex reduces the risk of free‑iron reactions, but clinicians still monitor for hypersensitivity and hypophosphatemia. Choice of product depends on patient needs, dosing convenience, and safety profile.

Injectafer must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Before use, inspect for particulate matter or discoloration; discard any product that appears compromised.

Injectafer is given as an intravenous infusion. The recommended infusion time varies with the total dose but typically ranges from 15 to 30 minutes. Administration should be performed by qualified healthcare personnel in a setting where vital signs can be monitored and emergency equipment is available.

Serious adverse events include anaphylactic or severe hypersensitivity reactions, marked hypophosphatemia, acute liver injury, and cardiovascular complications such as arrhythmias or myocardial ischemia. Patients should be observed during and after infusion, and any signs of severe reaction require immediate medical intervention.

Injectafer is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any of its excipients. It should also be avoided in individuals who have experienced severe anaphylactic reactions to other intravenous iron products. Caution is advised in patients with active infections, uncontrolled cardiac disease, or severe hepatic impairment.